Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab after lumbar fusion for lumbar spondylolisthesis
ChiCTR2100053047Phase 4Recruiting
- Sponsor
- Shenzhen People's Hospital
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of denosumab in osteoporosis and lumbar spondylolisthesis (2 arms), sponsored by Shenzhen People's Hospital. Primary endpoints: Osteocalcin N-terminal molecular fragment, Procollagen type 1 N-terminal propeptide (P1NP) and 10 more. Started Nov 2021; status: recruiting.
02
Drugs
denosumab
03
Conditions
osteoporosislumbar spondylolisthesis
Beyond the preview
Go deeper on ChiCTR2100053047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053047.